![Phil L'Huillier](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Phil L'Huillier
Chief Executive Officer at CatalYm GmbH
Profile
Phil L'Huillier is currently the Chief Executive Officer & Managing Director at CatalYm GmbH since 2021.
Prior to this, he worked as the Chief Executive Officer & Chief Scientific Officer at ProBio, Inc. He also worked as a Director & Director-Business Management at Cancer Research Technology Ltd.
In addition, he served as a Non-Executive Director at Hybrid BioSystems Ltd.
from 2009 to 2010.
He also worked as a Principal at CRT Group Plc and Biofocus Discovery Ltd.
Phil L'Huillier active positions
Companies | Position | Start |
---|---|---|
CatalYm GmbH
![]() CatalYm GmbH Pharmaceuticals: MajorHealth Technology CatalYm GmbH specializes in catalyzing immunotherapy. The company is headquartered in Munich, Germany. | Chief Executive Officer | 16/05/2021 |
Former positions of Phil L'Huillier
Companies | Position | End |
---|---|---|
Hybrid BioSystems Ltd.
![]() Hybrid BioSystems Ltd. Miscellaneous Commercial ServicesCommercial Services Hybrid is an Oxford Biotechnology Company focused on revolutionizing viral vaccines with its patented vaccine delivery technologies. Hybrid has an established and well equipped laboratory located at Cherwell Innovation Centre in Oxford shire, which houses both its corporate research facility and contract research services. Using a mixed product and platform business model it is developing its in-house lead products towards phase I/II proof of concept clinical trials as well as furthering its partnerships with leading pharmaceutical and biotechnology companies. Hybrid's experienced scientific and management team has reached this late stage of development through a highly efficient use of grant funding and revenues, together with minimal seed funding. With its unparalleled expertise in the field of viral steal thing technologies, The firm is also able to offer general and bespoke virology services, including high-quality adenovirus production and purification. Hybrid BioSystems uses iLabber electronic lab books for maximum IP protection and secure data storage. | Director/Board Member | 14/12/2010 |
Biofocus Discovery Ltd. | Corporate Officer/Principal | - |
CRT Group Plc | Corporate Officer/Principal | - |
ProBio, Inc.
![]() ProBio, Inc. Miscellaneous Commercial ServicesCommercial Services ProBio, Inc. provided animal reproductive, modification, and associated technologies for use in agriculture and medicine. The company was headquartered in Honolulu, HI. | President | - |
Cancer Research Technology Ltd.
![]() Cancer Research Technology Ltd. Medical SpecialtiesHealth Technology Cancer Research Technology Ltd. develops cancer therapeutics, vaccines, and diagnostics. The firm also provides project development, commercialization, drug discovery, clinical development, imaging, and funding services. The company was founded in 2002 and is headquartered in London, the United Kingdom. | Director/Board Member | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 6 |
---|---|
CRT Group Plc | |
ProBio, Inc.
![]() ProBio, Inc. Miscellaneous Commercial ServicesCommercial Services ProBio, Inc. provided animal reproductive, modification, and associated technologies for use in agriculture and medicine. The company was headquartered in Honolulu, HI. | Commercial Services |
Cancer Research Technology Ltd.
![]() Cancer Research Technology Ltd. Medical SpecialtiesHealth Technology Cancer Research Technology Ltd. develops cancer therapeutics, vaccines, and diagnostics. The firm also provides project development, commercialization, drug discovery, clinical development, imaging, and funding services. The company was founded in 2002 and is headquartered in London, the United Kingdom. | Health Technology |
Hybrid BioSystems Ltd.
![]() Hybrid BioSystems Ltd. Miscellaneous Commercial ServicesCommercial Services Hybrid is an Oxford Biotechnology Company focused on revolutionizing viral vaccines with its patented vaccine delivery technologies. Hybrid has an established and well equipped laboratory located at Cherwell Innovation Centre in Oxford shire, which houses both its corporate research facility and contract research services. Using a mixed product and platform business model it is developing its in-house lead products towards phase I/II proof of concept clinical trials as well as furthering its partnerships with leading pharmaceutical and biotechnology companies. Hybrid's experienced scientific and management team has reached this late stage of development through a highly efficient use of grant funding and revenues, together with minimal seed funding. With its unparalleled expertise in the field of viral steal thing technologies, The firm is also able to offer general and bespoke virology services, including high-quality adenovirus production and purification. Hybrid BioSystems uses iLabber electronic lab books for maximum IP protection and secure data storage. | Commercial Services |
Biofocus Discovery Ltd. | |
CatalYm GmbH
![]() CatalYm GmbH Pharmaceuticals: MajorHealth Technology CatalYm GmbH specializes in catalyzing immunotherapy. The company is headquartered in Munich, Germany. | Health Technology |
- Stock Market
- Insiders
- Phil L'Huillier